Onatasertib - Celgene
Alternative Names: ATG 008; CC 223Latest Information Update: 29 Jan 2024
At a glance
- Originator Celgene Corporation
- Developer Antengene Corporation; Celgene Corporation
- Class Antineoplastics; Pyrazines; Pyridines; Small molecules
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Liver cancer; Non-small cell lung cancer; Solid tumours
- Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma
- Phase I Diffuse large B cell lymphoma
- No development reported Prostate cancer
Most Recent Events
- 12 Dec 2023 Celgene terminates a phase I trial in Diffuse large B-cell lymphoma (Combination therapy, Second-line therapy or greater) in Canada, Italy, USA and France (PO) as the trial was replaced with another clinical trial (NCT02031419)
- 17 Nov 2023 Updated efficacy data from the TORCH-2 phase I/II trial in Solid tumours released by Antengene Corporation
- 25 Aug 2023 Updated efficacy data from the TORCH-2 phase I/II trial in Solid tumours released by Antengene Corporation